Osteoporosis Health Center
Calcitonin for Paget's disease of bone
Examples
| Generic Name | Brand Name |
|---|---|
| calcitonin-human | Cibacalcin |
| calcitonin-salmon | Calcimar, Miacalcin |
Calcitonin is available for injection either under the skin (subcutaneous or subQ injection) or into the muscle (intramuscular or IM injection). Miacalcin is available in a nasal spray, but it is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of Paget's disease.
How It Works
Calcitonin slows bone breakdown and rebuilding. It is injected under the skin for the treatment of Paget's disease.
Why It Is Used
People use calcitonin to control symptoms of Paget's disease and to slow the process of bone tissue breaking down and rebuilding too quickly. Doctors also may prescribe it to help prevent complications in people with Paget's disease who do not yet have symptoms.
How Well It Works
Calcitonin helps manage bone pain, may relieve some symptoms of nerve problems such as ringing in the ears or dizziness, and may slow the progress of hearing loss. 1
Calcitonin may prevent future hearing loss, but it will not repair hearing loss that has already occurred.
The benefits of calcitonin may take many weeks to notice, and they often go away soon after the person stops taking the medicine. Calcitonin does not slow or eliminate disease activity as well as bisphosphonates do. 2
Side Effects
You may feel sick to your stomach (nausea) after you receive a shot of calcitonin. But nausea usually gets better over time. Less common side effects of calcitonin include:
- Suddenly feeling very hot (flushed).
- Vomiting.
- Diarrhea.
- Abdominal pain.
Taking the medicine in the evening after dinner can reduce side effects.
See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)
What To Think About
You must take the injection form of calcitonin daily or at least several times a week. You or a family member can usually learn how to give the shot properly. It is important not to give the shot in the same place twice in a row. Changing places where the shots are given prevents damage to muscle tissue.
Some people develop a resistance to calcitonin. The medicine then stops working, and the disease becomes active again. Bisphosphonates appear to keep Paget's disease in an inactive state longer than calcitonin does.
The effects of calcitonin go away within a few months after you stop taking the medicine.
Miacalcin is available in a nasal spray. But this form has not been well-tested for Paget's disease.
Complete the new medication information form (PDF)
(What is a PDF document?) to help you understand this medication.
Citations
Kanis JA (2004). Paget's disease of bone (osteitis deformans). In L Goldman, D Ausiello, eds., Cecil Textbook of Medicine, 22nd ed., vol. 2, pp. 1579–1582. Philadelphia: Saunders.
Altman RD (2005). Paget's disease of bone. In WJ Koopman, LW Moreland, eds., Arthritis and Allied Conditions: A Textbook of Rheumatology, 15th ed., vol. 2, pp. 2543–2557. Philadelphia: Lippincott Williams and Wilkins.
WebMD Medical Reference from Healthwise
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRIPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.

